Panel Discussion: Exploring Next-Generation Nanoparticle Systems Beyond LNPs to Expand Extrahepatic Targeting, Improve Safety, & Enable Broader Therapeutic Delivery
9:30 am - Thursday 4th June 2026
- Where do LNPs begin to show limitations for extrahepatic delivery and which emerging delivery vehicles offer the most realistic advantages?
- How do alternative delivery platforms compare in terms of manufacturability, scalability, safety, and regulatory readiness when moving towards the clinic?
- Which delivery challenges, from immunogenicity to targeting specificity, are best addressed by exploring non-LNP platforms, and where do LNPs remain the most practical solution?
